Business Description
Vericel Corp
NAICS : 541715
SIC : 2836
ISIN : US92346J1088
Description
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.04 | |||||
| Equity-to-Asset | 0.66 | |||||
| Debt-to-Equity | 0.38 | |||||
| Debt-to-EBITDA | 9.34 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 12.41 | |||||
| Beneish M-Score | -2.7 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 16.5 | |||||
| 3-Year EBITDA Growth Rate | -19.5 | |||||
| 3-Year FCF Growth Rate | -19.6 | |||||
| 3-Year Book Growth Rate | 17.2 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 22.65 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.44 | |||||
| 9-Day RSI | 57.37 | |||||
| 14-Day RSI | 60.66 | |||||
| 3-1 Month Momentum % | 20.93 | |||||
| 6-1 Month Momentum % | 27.96 | |||||
| 12-1 Month Momentum % | 55.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.61 | |||||
| Quick Ratio | 4.23 | |||||
| Cash Ratio | 2.46 | |||||
| Days Inventory | 78.84 | |||||
| Days Sales Outstanding | 78.68 | |||||
| Days Payable | 116.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.5 | |||||
| Shareholder Yield % | -1.63 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 71.47 | |||||
| Operating Margin % | -0.54 | |||||
| Net Margin % | 1.56 | |||||
| FCF Margin % | -5.3 | |||||
| ROE % | 1.52 | |||||
| ROA % | 0.99 | |||||
| ROIC % | -0.41 | |||||
| 3-Year ROIIC % | -11.27 | |||||
| ROC (Joel Greenblatt) % | 2.85 | |||||
| ROCE % | 1.65 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 821 | |||||
| Forward PE Ratio | 123.33 | |||||
| PE Ratio without NRI | 821 | |||||
| PS Ratio | 12.26 | |||||
| PB Ratio | 11 | |||||
| Price-to-Tangible-Book | 11.28 | |||||
| Price-to-Operating-Cash-Flow | 60.56 | |||||
| EV-to-EBIT | 538.06 | |||||
| EV-to-EBITDA | 271.3 | |||||
| EV-to-Revenue | 12.49 | |||||
| EV-to-Forward-Revenue | 9.43 | |||||
| EV-to-FCF | -235.74 | |||||
| Price-to-GF-Value | 1.26 | |||||
| Price-to-Projected-FCF | 10.35 | |||||
| Price-to-Median-PS-Value | 1.74 | |||||
| Price-to-Graham-Number | 20.31 | |||||
| Price-to-Net-Current-Asset-Value | 49.12 | |||||
| Earnings Yield (Greenblatt) % | 0.19 | |||||
| FCF Yield % | -0.42 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VCEL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vericel Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 226.844 | ||
| EPS (TTM) ($) | 0.07 | ||
| Beta | 1.16 | ||
| 3-Year Sharpe Ratio | 0.47 | ||
| 3-Year Sortino Ratio | 0.76 | ||
| Volatility % | 46.87 | ||
| 14-Day RSI | 60.66 | ||
| 14-Day ATR ($) | 2.285476 | ||
| 20-Day SMA ($) | 57.0945 | ||
| 12-1 Month Momentum % | 55.86 | ||
| 52-Week Range ($) | 32.31 - 61.49 | ||
| Shares Outstanding (Mil) | 49.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vericel Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vericel Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Vericel Corp Frequently Asked Questions
What is Vericel Corp(VCEL)'s stock price today?
The current price of VCEL is $57.47. The 52 week high of VCEL is $61.49 and 52 week low is $32.31.
When is next earnings date of Vericel Corp(VCEL)?
The next earnings date of Vericel Corp(VCEL) is 2025-02-28 Est..
Does Vericel Corp(VCEL) pay dividends? If so, how much?
Vericel Corp(VCEL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers